The study details the discovery of a species of Burkholderia gladioli isolated from the saliva and mucus of a pediatric cystic fibrosis patient. The bacterium produces an antibiotic called gladiolin, which was found to be active against multiple isolates of drug-resistant strains of TB in the laboratory setting.
“Overall, these data suggest that gladiolin may represent a useful starting point for the development of novel drugs to tackle multidrug-resistant TB,” wrote the study’s authors.
To learn more about drug-resistant TB, click here.
More articles on infection control:
Chronic Lyme disease treatments put patients at risk for serious harm, says CDC
The Joint Commission releases compendium of VTE care resources
CRE endemic across DC healthcare facilities, study suggests
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.